NRx Pharmaceuticals Presents Evidence ZYESAMI™ (aviptadil) Helps Prevent “Cytokine Storm” in Patients with COVID-19

July 19, 2021
10:48 am

NRx Pharmaceuticals Presents Evidence ZYESAMI™ (aviptadil) Helps Prevent “Cytokine Storm” in Patients with COVID-19

NRx Pharmaceuticals Presents Evidence ZYESAMI (aviptadil) Helps Prevent “Cytokine Storm” in Patients with COVID-19
Tweet this
Health regulators continue to prioritize therapies for COVID-19 which help block the impact of IL-6 cytokines in patients with…

Click here to view the original article.

Global, PRNewswire

Share this article

Welcome to the post-hype crypto market

February 25, 2026

Is Lumen Technologies (LUMN) Still Appealing After Recent Share Price Pullback?

February 25, 2026

FCA Picks Four Firms for Stablecoin Trials in Sandbox Ahead of Next Year’s Crypto Rules

February 25, 2026

Is Navan (NAVN) Offering An Opportunity After Recent Share Price Pullback?

February 25, 2026

The chief of the SEC is headlining an event sponsored by a crypto firm at war with it

February 25, 2026

Is Dole (DOLE) Stock Pricing In Its Strong Multi Year Share Price Performance?

February 25, 2026

South Korea Lawmaker Pushes Crypto Influencer Disclosure Bill

February 25, 2026

GE Vernova is Sold Out and Scaling Up: Why Its 83-Gigawatt Backlog Could Point to $2,700 Stock Price

February 25, 2026